Ramucirumab Shows Survival Benefits with Pleural Mesothelioma

    Research & Clinical Trials

    Our fact-checking process begins with a thorough review of all sources to ensure they are high quality. Then we cross-check the facts with original medical or scientific reports published by those sources, or we validate the facts with reputable news organizations, medical and scientific experts and other health experts. Each page includes all sources for full transparency.

    Adding the drug ramucirumab to gemcitabine chemotherapy worked especially well in a recent clinical trial involving second-line treatment for patients with pleural mesothelioma.

    Ramucirumab, an immunotherapy drug also known by the brand name Cyramza, is a monoclonal antibody that works by targeting and restricting a protein that stimulates blood vessel growth within tumors.

    Impressive results in the phase II clinical trial moved the drug combination closer to filling the long-standing void for a second-line mesothelioma treatment.

    The Lancet Oncology recently published results of the study, which was conducted in 26 hospitals throughout Italy.

    “This combination could be a novel, well-tolerated and active treatment option for patients who have progressed on first-line chemotherapy,” the authors wrote. “The overall survival gain was achieved without a marked increase in toxicity.”

    See also  New Report Details 9/11 Health Effects on FDNY Firefighters
    See also  Mesothelioma Research Grants Focus on Immunotherapy

    Addition of Immunotherapy Boosts Survival

    The randomized, double-blind, placebo-controlled trial involved 161 pretreated patients. Eighty patients received the combination treatment, while 81 received gemcitabine and a placebo.

    All participants had experienced disease progression after the inevitable failure of traditional first-line treatment of pemetrexed and cisplatin chemotherapy.

    Results, which were measured from the time of second-line treatment randomization, included:

    Gemcitabine/Ramucirumab vs. Gemcitabine/Placebo

    Ramucirumab Placebo
    Median overall survival 13.8 months 7.5 months
    6-month overall survival 76% 56.5%
    12-month overall survival 63.9% 33.9%
    Median progression-free survival 6.4 months 3.3 months
    Disease control rate 73% 52%
    Duration of response 8.4 months 5.4 months

    According to study authors, the clear advantage of adding ramucirumab came regardless of histological subtype and time-to-progression of earlier first-line treatment.

    “The results show that the addition of ramucirumab to gemcitabine can provide a notable improvement in overall survival,” the authors wrote. “This combination could be a new option in this setting.”

    Ramucirumab Approved for Other Cancers

    Ramucirumab, as a single drug or in combination with different chemotherapy agents, already has been approved for second-line treatment of colorectal cancer, non-small cell lung cancer, gastric adenocarcinoma and hepatocellular carcinoma.

    See also  Mesothelioma Research Grants Focus on Immunotherapy

    With pleural mesothelioma, a rare cancer with no definitive cure, gemcitabine is typically used alone in second-line treatment for patients hoping to extend survival. It has not been very effective for most patients on its own.

    See also  New Report Details 9/11 Health Effects on FDNY Firefighters

    In this latest study, adverse treatment side effects from the drug were not a big issue for most participants. Serious adverse events were reported in 6% of those receiving ramucirumab and 5% of those getting the placebo. The most common grade 3 or 4 adverse event was neutropenia, or low white blood cell count, in 20% of those receiving ramucirumab and 12% of those with the placebo.

    Additional Studies Show Effectiveness

    Marketed by Eli Lilly and Company, ramucirumab is receiving rave reviews for second-line treatment when used in combination with nivolumab (Opdivo), another immunotherapy, in an ongoing, multi-center phase II clinical trial in the United States.

    Oncologist Dr. Arek Dudek opened that trial initially at Regions Hospital Cancer Care Center in St. Paul, Minnesota, but it has been joined by the Moffitt Cancer Center in Tampa, Karmanos Cancer Center in Detroit and the Greenebaum Cancer Center in Baltimore. That trial is expected to conclude in 2022.

    See also  Mesothelioma Treatment Program Expanding in Central Florida

    “I’m hopeful that the results will change the way we treat this cancer,” Dudek said. “When chemotherapy fails a patient with mesothelioma, there isn’t much left to do. This combination brings a completely different level of engaging the immune system.”

    See also  Johnson & Johnson Weighs Options for Talc Liabilities

    The combination of nivolumab and ipilimumab was approved by the Food and Drug Administration in 2020, the first new systemic approval for mesothelioma in 15 years. Some patients are using it now in first-line treatment instead of the standard chemotherapy.

    Most oncologists today believe the future of mesothelioma treatment – like many cancers – will involve immunotherapy in some combination.

    The use of ramucirumab with chemotherapy could be part of the next second-line treatment advancement for pleural mesothelioma, which is caused by exposure to asbestos.

    “There is a substantial unmet need for new therapies in pretreated malignant pleural mesothelioma,” the authors concluded. “This combination warrants exploration in a further prospective phase III trial.”

    Connect with a Mesothelioma Doctor

    Find a Top Specialist Near You

    Related articles